Concord Biotech Ltd

Concord Biotech Bonus Issue

Concord Biotech's board recommended a 1:1 bonus share issue from free reserves. Shareholders will consider this proposal at an upcoming postal ballot on October 24, 2026.

Concord Biotech Bonus Issue

Concord Biotech approved a 1:1 bonus issue of 10.46 crore equity shares. The board also increased the company's authorized share capital to Rs. 22 Crore.

Value

₹10.46 Cr

Concord Biotech Board Meeting Date

Concord Biotech Ltd announced a board meeting for September 23, 2026, to consider a proposal for the declaration of bonus equity shares.

Concord Biotech Business Update

Concord Biotech disclosed a successful USFDA inspection at its Valthera facility with one minor non-GMP observation. No material impact on operations or existing supplies is expected.

Concord Biotech Earnings Call Transcript: Key Takeaways

Concord reports a strong 26% revenue recovery in Q1FY27, pivoting from a challenging FY26 despite previous procurement delays.

Concord Biotech Investor Presentation: Key Takeaways

Concord Biotech reported strong Q1FY27 consolidated performance with 26% revenue growth and 31% PAT growth, driven by a 46% surge in exports and expanding market share in niche fermentation APIs.

Concord Biotech Annual General Meeting

Concord Biotech Ltd held its 41st Annual General Meeting on July 31, 2026, via video conferencing. The company summarized the proceedings and acknowledged participant queries.

Concord Biotech Q1 FY27 Results: Net Profit ₹57.7 Cr, Up 30.8% YoY

Concord Biotech Ltd reported revenue from operations of ₹257.5 Cr (+26.2% YoY) and net profit of ₹57.7 Cr (+30.8% YoY) for Q1 FY27.

Key figure

Net profit ₹57.7 Cr · +30.8% YoY

Concord Biotech Board Meeting Date

Concord Biotech will hold a Board Meeting on July 31, 2026, to consider and approve the unaudited standalone and consolidated financial results.

Concord Biotech Other Announcement

Concord Biotech Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026. This is a routine regulatory compliance disclosure under SEBI LODR.

Concord Biotech Business Update

Concord Biotech filed its BRSR for FY 2025-26, detailing ESG metrics and operations. The report is a routine compliance filing with no financial or structural impact.

Concord Biotech Annual Report

Concord Biotech Ltd filed its Annual Report for FY 2025-26. The report covers corporate overview, management reports, and financial statements ending March 31, 2026.

Concord Biotech Annual General Meeting

Concord Biotech Ltd. has issued notice for its 41st AGM on July 31, 2026. The meeting will transact financial statements, dividend, and director appointments via VC/OAVM.

Concord Biotech Legal & Regulatory

Concord Biotech filed a Certificate under SEBI Regulation 74(5) confirming dematerialisation of securities for Q June 2026. The filing is submitted to NSE and BSE.

Concord Biotech Regulatory Approval

Concord Biotech announced successful completion of inspections by Kenya's PPB and Uganda's NDA at its Unit-II formulation facility. The milestone enhances its global regulatory footprint.

Concord Biotech Other Announcement

Concord Biotech confirmed the successful completion of the ANVISA inspection at its Limbasi API plant. This strengthens its regulatory standing and supports global expansion.

Concord Biotech Regulatory Approval

Concord Biotech received USFDA approval for Tofacitinib Tablets (5mg and 10mg). The approval targets a US$ 500 million market, strengthening the company's US pharmaceutical footprint.

Concord Biotech Earnings Call: Key Takeaways

Concord Biotech reported a challenging FY26 with a 12% revenue decline and 30% PAT drop due to geopolitical headwinds, tender delays, and regulatory holdups. Management remains optimistic for a stronger FY27.

Concord Biotech Regulatory Approval

Concord Biotech received USFDA approval for its Mycophenolate Mofetil Oral Suspension ANDA. This approval strengthens the company's position in the US$ 30 million U.S. market.

Concord Biotech Earnings Call: Key Takeaways

FY26 was a rough year marked by geopolitical disruptions and US procurement slowdowns. Management pivots to a recovery narrative for FY27, banking on new injectable facilities and US direct marketing to reverse recent de-growth.

Concord Biotech Earnings Call: Key Takeaways

Concord Biotech reported a challenging FY26 with consolidated revenue at ₹1,054.9 Cr (-12% YoY) and PAT at ₹259.2 Cr (-30% YoY) due to procurement delays and geopolitical issues.

Concord Biotech Management Change

Concord Biotech appointed Mrs. Ekta Sanghi Gupta as Independent Director for a five-year term effective June 2026. The board also re-appointed its internal and cost auditors.

Execution

60 months

Concord Biotech Dividend

Concord Biotech recommended a final dividend of ₹7.55 per equity share for FY 2025-26. The record date for payment is July 24, 2026.

Concord Biotech Q4 FY26 Results: Net Profit ₹88.5 Cr, Down 37.0% YoY

Concord Biotech Ltd reported revenue from operations of ₹326.1 Cr (-24.1% YoY) and net profit of ₹88.5 Cr (-37.0% YoY) for Q4 FY26.

Key figure

Net profit ₹88.5 Cr · -37.0% YoY

Concord Biotech Financial Results

Concord Biotech approved its FY26 audited financial results and recommended a final dividend of Rs. 7.55 per share. It also appointed Mrs. Ekta Gupta as an Additional Independent Director.

Concord Biotech Board Meeting Date

Concord Biotech scheduled a board meeting on May 29, 2026, to approve annual financial results. The board will also consider recommending a final dividend.

Concord Biotech Other Announcement

Concord Biotech Limited submitted a compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The Registrar and Share Transfer Agent, MUFG Intime India, confirmed that no dematerialization or rematerialization requests were received during this period.